HCP Marketing Lead, HAE, Global Rare Diseases; Boston, MA,

About Us

Based in Parma, Italy, Chiesi is an international research-focused biopharmaceutical group with 90 years’ experience, operating in 31 countries. More than 8,000 employees across the group are united by a singular purpose: promoting a healthier world for our people, patients, and the planet. This is what drives us as we research, develop, and market innovative drugs across our main therapeutic areas.

Discover more here.

At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. This fosters a culture of reliability, transparency, and ethical behaviour at every level. As a Benefit Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact.

Diversity, inclusion, and equal opportunity are at the heart of who we are. We believe our differences make us stronger. We are a vibrant ecosystem of passionate, talented individuals united by strong values, each bringing unique perspectives that help us to continuously challenge the status quo for the better.

Chiesi Global Rare Diseases is a Chiesi Group’s business unit established in February 2020 and focused on research, development and commercialization of treatments and patient support services for rare and ultra-rare disorders, many of whom have limited or no treatments available.

This unit is based in Boston, Massachusetts, with a strong synergy with the headquarters in Parma.

Rare unit has a focus on research and product development for lysosomal storage diseases, rare hematology, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. Discover more here.

Reporting to the Head of Ekterly Marketing-U.S., this position is responsible for developing HCP strategy and leading tactical execution. The role works cross-functionally to develop and implement personal and non-personal promotional initiatives, while supporting key marketing processes including brand planning, launch readiness, budget management and quarterly business reviews.

EKTERLY (sebetralstat) is a plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland and Australia for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is the first and only oral on-demand HAE treatment. Ongoing studies are evaluating use in children aged 2 to 11 years, with additional regulatory reviews underway in other markets.

You’ll be responsible for:

• Support disease-state strategy, campaigns, messaging, targeting and market-development tactics before and after launch.
• Support brand strategy development and continued launch execution.
• Lead peer-to-peer strategy and execution, including congresses, advisory boards, speaker bureaus and speaker education programs
• Manage congress strategy, exhibit design, sponsor ships and commercial events.
• Gather market insights to inform launch strategies.
• Develop and execute personal and non-personal launch tactics.
• Partner with Sales leadership to ensure readiness of materials, training and launch support.
• Manage agency partners, budgets, forecasts, project timelines and promotional review processes.
• Work closely with Legal, Regulatory and Medical Affairs to ensure compliant promotional materials.
• Manage multiple simultaneous projects, ensuring delivery on time and within budget. Support transfer of value reporting in accordance with state and federal requirements.

• Education:
  
  Bachelor’s degree required.
• Preferred experience in HAE market
• 10+ years of pharmaceutical/biotech experience.
• 5+ years in marketing.
• E…